Palisade Bio Inc (PALI) Stock Price, Quote & News

Company Profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pha...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 704 4900

Website: www.palisadebio.com

Address:

4600 South Syracuse Street, Suite 900, Denver, United States

Toadvind Jun. 6 at 9:52 PM

$PALI buy under 1.80, sell over 2.30 rinse repeat

0 · Reply

WhiteFang420 Jun. 2 at 3:49 PM

$PALI I expect to see this @ 1.80 minimum, prolly lower.

1 · Reply

masonat Jun. 1 at 9:49 PM

$PALI Okay I wasn't going to complain as it followed ABVX up but it makes no sense for it to follow it down either 🤣

0 · Reply

dl42 Jun. 1 at 9:37 PM

$PALI wow up to 2.50 and down to this. It sounds like a big misunderstanding around potential malignancies is ABVX data.

1 · Reply

Pdior77 Jun. 1 at 9:00 PM

$PALI what the fuck

0 · Reply

masonat Jun. 1 at 8:25 PM

$PALI Thank you $ABVX for the bump 🤷🏻

1 · Reply

lolyeah Jun. 1 at 8:21 PM

$PALI what happened here?

0 · Reply

specctham May. 24 at 5:31 PM

$PALI Wen 5?

1 · Reply

LoveRetailFroth May. 20 at 1:22 PM

$PALI Good Morning ☕️ Still holding my 50k. Give it a few months

0 · Reply

MNJ7777777 May. 13 at 2:29 PM

$PALI MXCT announced a share repurchase program this morning.

0 · Reply

Palisade Bio Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 7:00 AM EDT - 4 days ago

Palisade Bio Slides: Corporate presentation

May 27, 2026, 9:00 AM EDT - 12 days ago

Palisade Bio to Participate in the Jefferies Global Healthcare Conference

May 13, 2026, 7:00 AM EDT - 26 days ago

Palisade Bio Slides: Corporate presentation

2026-05-12T22:21:57.000Z - 27 days ago

Palisade Bio files $300M mixed securities shelf

May 12, 2026, 4:15 PM EDT - 27 days ago

Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108

May 12, 2026, 8:00 AM EDT - 27 days ago

Palisade Bio Registration statement: Registration filing

May 12, 2026, 7:00 AM EDT - 27 days ago

Palisade Bio Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 27 days ago

Palisade Bio Earnings release: Q1 2026

May 5, 2026, 8:30 AM EDT - 4 weeks ago

Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

Palisade Bio Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

Palisade Bio Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 7 weeks ago

Palisade Bio Proxy statement: Proxy filing

Apr 16, 2026, 2:15 PM EDT - 7 weeks ago

Palisade Bio Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 16, 2026, 8:50 AM EDT - 7 weeks ago

Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026

2026-04-08T20:43:15.000Z - 2 months ago

Palisade Bio initiated with an Outperform at Wolfe Research

Apr 8, 2026, 9:00 AM EDT - 2 months ago

Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference

Apr 1, 2026, 7:00 AM EDT - 2 months ago

Palisade Bio Slides: Corporate presentation

2026-03-31T20:38:39.000Z - 2 months ago

Palisade Bio reaction to PALI-2108 data ‘looks misaligned’, says Clear Street

Mar 31, 2026, 8:00 AM EDT - 2 months ago

Palisade Bio Transcript: Study result

Mar 31, 2026, 8:00 AM EDT - 2 months ago

Palisade Bio Press release: Study result

Mar 31, 2026, 8:00 AM EDT - 2 months ago

Palisade Bio Slides: Study result

2026-03-30T20:19:16.000Z - 2 months ago

Palisade Bio announces topline data from PALI-2108 trial

Mar 30, 2026, 4:01 PM EDT - 2 months ago

Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease

2026-03-26T10:11:33.000Z - 2 months ago

Palisade Bio initiated with a Buy at H.C. Wainwright

Mar 20, 2026, 7:00 AM EDT - 2 months ago

Palisade Bio Annual report: Q4 2025

Mar 18, 2026, 7:00 AM EDT - 2 months ago

Palisade Bio Slides: Corporate presentation

Mar 2, 2026, 3:10 PM EST - 3 months ago

Palisade Bio Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:00 AM EST - 3 months ago

Palisade Bio Announces Participation in Two Upcoming Investor Conferences

Feb 26, 2026, 12:40 PM EST - 3 months ago

Palisade Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-02-24T21:52:07.000Z - 3 months ago

Palisade Bio initiated with a Buy at Stifel

2026-02-23T13:47:18.000Z - 3 months ago

Palisade Bio announces presentation of new data for PALI-2108

Feb 23, 2026, 8:40 AM EST - 3 months ago

Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026

2026-02-17T14:05:21.000Z - 3 months ago

Palisade Bio appoints Verstockt to its Clinical Advisory Board

Feb 17, 2026, 8:45 AM EST - 3 months ago

Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

Feb 9, 2026, 9:00 AM EST - 4 months ago

Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 5, 2026, 8:45 AM EST - 4 months ago

Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-01-29T13:50:44.000Z - 4 months ago

Palisade Bio appoints Peyrin-Biroulet, Rubin to Clinical Advisory Board

Jan 29, 2026, 8:45 AM EST - 4 months ago

Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

Jan 16, 2026, 8:30 AM EST - 5 months ago

Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences

2026-01-09T10:35:21.000Z - 5 months ago

Palisade Bio initiated with a Buy at B. Riley

2026-01-07T13:25:34.000Z - 5 months ago

Palisade Bio announces equity investment from Crohn’s & Colitis Foundation

Jan 7, 2026, 8:15 AM EST - 5 months ago

Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108

2025-12-30T13:45:55.000Z - 5 months ago

Palisade Bio granted Japanese patent covering PALI-2108

Dec 30, 2025, 8:35 AM EST - 5 months ago

Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108

2025-12-29T21:10:18.000Z - 5 months ago

Palisade Bio initiated with a Buy at Clear Street

2025-12-29T09:30:14.000Z - 5 months ago

Palisade Bio initiated with an Overweight at Piper Sandler

Dec 4, 2025, 10:30 AM EST - 6 months ago

Palisade Bio Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-12-02T13:55:38.000Z - 6 months ago

Palisade Bio appoints James Izanec as VP, clinical development

BMY

Dec 2, 2025, 8:45 AM EST - 6 months ago

Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

Nov 25, 2025, 8:45 AM EST - 6 months ago

Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference

2025-11-11T17:45:32.000Z - 7 months ago

Palisade Bio price target raised to $8 from $2 at Maxim

Nov 10, 2025, 4:00 PM EST - 7 months ago

Palisade Bio Quarterly report: Q3 2025

Nov 3, 2025, 7:00 AM EST - 7 months ago

Palisade Bio Proxy statement: Proxy Filing

2025-10-28T12:50:12.000Z - 7 months ago

Palisade Bio appoints Sharon Skare as global head, clinical operations

Oct 28, 2025, 8:45 AM EDT - 7 months ago

Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations

Oct 28, 2025, 8:00 AM EDT - 7 months ago

Palisade Bio Proxy statement: Proxy Filing

2025-10-20T12:52:57.000Z - 8 months ago

Palisade Bio announces first patients dosed in Phase 1b study of PALI-2108

Oct 20, 2025, 8:45 AM EDT - 8 months ago

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD)

Oct 17, 2025, 8:00 AM EDT - 8 months ago

Palisade Bio Proxy statement: Proxy Filing

Oct 15, 2025, 6:00 PM EDT - 8 months ago

Palisade Bio Slides: Corporate Presentation

2025-10-13T12:50:05.000Z - 8 months ago

Palisade Bio granted Canadian patent covering PALI-2108 composition

Oct 13, 2025, 8:45 AM EDT - 8 months ago

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

Oct 9, 2025, 5:00 PM EDT - 8 months ago

Palisade Bio Announces Cancellation of Special Meeting of Stockholders

Oct 7, 2025, 8:00 AM EDT - 8 months ago

Palisade Bio Proxy statement: Proxy Filing

Oct 2, 2025, 4:05 PM EDT - 8 months ago

Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option

Oct 1, 2025, 9:20 AM EDT - 8 months ago

Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock

Sep 29, 2025, 8:00 AM EDT - 9 months ago

Palisade Bio Registration statement: Registration Filing

Sep 26, 2025, 4:05 PM EDT - 9 months ago

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

Sep 17, 2025, 9:00 AM EDT - 9 months ago

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data

Sep 15, 2025, 8:00 AM EDT - 9 months ago

Palisade Bio Proxy statement: Proxy Filing

Sep 15, 2025, 8:00 AM EDT - 9 months ago

Palisade Bio Proxy statement: Proxy Filing

Sep 5, 2025, 8:45 AM EDT - 9 months ago

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)

Sep 5, 2025, 8:00 AM EDT - 9 months ago

Palisade Bio Proxy statement: Proxy Filing

Aug 25, 2025, 9:00 AM EDT - 10 months ago

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

Aug 18, 2025, 8:00 AM EDT - 10 months ago

Palisade Bio Proxy statement: Proxy Filing

Aug 15, 2025, 8:00 AM EDT - 10 months ago

Palisade Bio Registration statement: Registration Filing

Aug 11, 2025, 4:00 PM EDT - 10 months ago

Palisade Bio Quarterly report: Q2 2025

Aug 7, 2025, 9:15 AM EDT - 10 months ago

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

Aug 6, 2025, 8:00 AM EDT - 10 months ago

Palisade Bio Proxy statement: Proxy Filing

Jul 31, 2025, 8:45 AM EDT - 11 months ago

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

Jul 23, 2025, 8:00 PM EDT - 11 months ago

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

Jul 22, 2025, 8:45 AM EDT - 11 months ago

Palisade Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 9, 2025, 8:45 AM EDT - 11 months ago

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

May 27, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis

May 27, 2025, 8:00 AM EDT - 1 year ago

Palisade Bio Registration statement: Registration Filing

May 11, 2025, 6:00 PM EDT - 1 year ago

Palisade Bio Quarterly report: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

May 1, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

Apr 9, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Palisade Bio Annual report: Q4 2024

Mar 14, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

Mar 12, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

Mar 4, 2025, 8:30 AM EST - 1 year ago

Palisade Bio Participates in Virtual Investor “What This Means” Segment

Feb 20, 2025, 8:45 AM EST - 1 year ago

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

Feb 19, 2025, 9:00 AM EST - 1 year ago

Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 1 year ago

Palisade Bio Transcript: Virtual Investor "Top 5 for '25"

Feb 10, 2025, 8:45 AM EST - 1 year ago

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Jan 29, 2025, 8:45 AM EST - 1 year ago

Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress

Jan 3, 2025, 5:20 PM EST - 1 year ago

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 17, 2024, 8:30 AM EST - 1 year ago

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

Dec 13, 2024, 4:05 PM EST - 1 year ago

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Dec 12, 2024, 12:05 PM EST - 1 year ago

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Dec 9, 2024, 7:00 AM EST - 1 year ago

Palisade Bio Registration statement: Registration Filing

Dec 5, 2024, 7:00 AM EST - 1 year ago

Palisade Bio Registration statement: Registration Filing

Dec 3, 2024, 8:15 AM EST - 1 year ago

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

Nov 21, 2024, 8:15 AM EST - 1 year ago

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

Toadvind Jun. 6 at 9:52 PM

$PALI buy under 1.80, sell over 2.30 rinse repeat

0 · Reply

WhiteFang420 Jun. 2 at 3:49 PM

$PALI I expect to see this @ 1.80 minimum, prolly lower.

1 · Reply

masonat Jun. 1 at 9:49 PM

$PALI Okay I wasn't going to complain as it followed ABVX up but it makes no sense for it to follow it down either 🤣

0 · Reply

dl42 Jun. 1 at 9:37 PM

$PALI wow up to 2.50 and down to this. It sounds like a big misunderstanding around potential malignancies is ABVX data.

1 · Reply

Pdior77 Jun. 1 at 9:00 PM

$PALI what the fuck

0 · Reply

masonat Jun. 1 at 8:25 PM

$PALI Thank you $ABVX for the bump 🤷🏻

1 · Reply

lolyeah Jun. 1 at 8:21 PM

$PALI what happened here?

0 · Reply

specctham May. 24 at 5:31 PM

$PALI Wen 5?

1 · Reply

LoveRetailFroth May. 20 at 1:22 PM

$PALI Good Morning ☕️ Still holding my 50k. Give it a few months

0 · Reply

MNJ7777777 May. 13 at 2:29 PM

$PALI MXCT announced a share repurchase program this morning.

0 · Reply

Readcarefully May. 13 at 9:53 AM

$PALI Very good news: "As of March 31, 2026, the Company had cash and cash equivalents of $132.6 million and believes that its cash on hand is sufficient to fund its operations through major clinical development milestones, including a Phase 2 primary efficacy readout of PALI-2108 for UC that is expected in the second half of 2027 and a Phase 2 primary efficacy readout of PALI-2108 CD that is expected in early 2028." https://finance.yahoo.com/news/palisade-bio-reports-first-quarter-201500467.html

0 · Reply

buymoremakemore May. 12 at 11:29 PM

$PALI I am from the Pacific Palisades. My house burnt down last year. Let’s not burn down another Palisades with this shelf BS

0 · Reply

TwongStocks May. 12 at 9:52 PM

$PALI $300M shelf registration statement filed https://www.sec.gov/Archives/edgar/data/1357459/000149315226022548/forms-3.htm

0 · Reply

d_risk May. 12 at 8:28 PM

$PALI - PALISADE BIO, INC. - 10Q - Updated Risk Factors PALI’s 10-Q sharpens its “all eggs in one basket” risk: the company now squarely ties its survival to PALI-2108, stressing fragile licensing, foreign trial data risk, heavy funding needs, third‑party dependencies, shifting healthcare law and pricing pressure, and its lack of any approved products or proven commercial model. #Biotechnology #ClinicalTrialsRisk #RegulatoryUncertainty #FundingDependency #HealthcarePricingPressure 🟢 Added 🟠 Removed https://d-risk.ai/PALI/10-Q/2026-05-12

0 · Reply

TwongStocks May. 12 at 8:17 PM

$PALI 10-Q filed https://www.sec.gov/ix?doc=/Archives/edgar/data/1357459/000135745926000010/pali-20260331.htm • 173,579,670 shares outstanding as of May 7 • $132.6M as of Mar 31

1 · Reply

BOUDIN420 May. 8 at 7:50 PM

$PALI soaking these at $1.80

0 · Reply

companyofone May. 8 at 7:03 PM

$PALI voted against adding another 150 million shares like wtf

1 · Reply

Readcarefully May. 7 at 6:50 AM

$PALI This is new: "Precision Medicine CDx test in development to identify UC patient responders to PDE4 inhibitors, ensuring better treatment outcomes" That would be totally disruptive and increase the market value x3 https://d2ghdaxqb194v2.cloudfront.net/2827/199934.pdf

1 · Reply

Readcarefully May. 6 at 6:42 AM

$PALI Why PALI will continue to show better results than Mufemilast. Mufemilast already shows exceptional results in UC, but PALI is even better because: 1. Local activation because of the prodrug mechanism --> higher concentration of the medication in the inflamed tissue 2. Less adverse events --> higher dosages possible 3. Longer half life --> more stable and constant PDE4-inhibition 4. Faster respons of the biomarkers --> predictor of higher remission

0 · Reply

100K2022 May. 5 at 8:00 PM

$PALI what’s going on here?

1 · Reply

SkywalkerAR May. 5 at 5:42 PM

$PALI https://palisadebio.com/palisade-bio-reports-additional-phase-1a-b-data-demonstrating-colon-targeted-exposure-and-sustained-ic90-coverage-supporting-once-daily-dosing-in-ulcerative-colitis/

0 · Reply

Unicorno May. 5 at 3:27 PM

$PALI mufemilast data confirm pde4 very effective in UC just presented at DDW! mufemilast data ill remain in china so palisade green light

0 · Reply

Market Cap	302.03M
Revenue (ttm)	0.00
Net Income (ttm)	-16.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,100,700
Avg Vol	3,867,742
Day's Range	N/A - N/A
Shares Out	173.58M
Stochastic %K	16%
Beta	1.52
Analysts	Strong Sell
Price Target	$10.00